Glaxosmithkline Pharma Peer Comparison

NSE: GLAXO | BSE: 500660

₹2,732.80

₹-38.30 (-1.38%)

As on 05-Oct-2026IST

Market cap

₹46,320 Cr

Revenue (TTM)

₹3,955 Cr

P/E Ratio

43.4

P/B Ratio

18.4

Div. Yield

2.1 %

Edit

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Market cap (₹ Cr)	46,320	1,13,566	1,02,433	1,00,829	96,088
Revenue (₹ Cr)	3,955	28,592	14,738	33,228	34,935
Net Profit (₹ Cr)	1,068.15	4,492.20	2,055.11	3,169.30	3,712.74
Net Margin (%)	26.05	14.92	13.64	9.15	10.42
RoE (%)	52.98	18.78	13.60	8.72	10.38
Price to Earnings	43.36	25.16	50.15	31.29	25.88
Price-To-Book	18.38	4.21	6.09	2.64	2.47

Income Statement (₹ Cr)

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Operating Revenue	3,954.94	28,591.70	14,737.88	33,227.90	34,935.29
Total Income	4,100.34	30,111.40	15,061.79	34,650.70	35,624.79
Total Expenditure	2,601.44	21,334.70	10,911.05	28,088.10	27,850.01
EBITDA	1,353.50	7,257.00	3,826.83	5,139.80	7,085.28
Depreciation	66.76	1,724.60	893.20	2,119.30	1,859.31
EBIT	1,286.74	5,532.40	2,933.63	3,020.50	5,225.97
Interest	3.28	510.20	578.61	416.30	387.88
Other Income	145.40	1,519.70	323.91	1,422.80	689.50
Exceptional Items	20.62	-534.80	-129.75	0.00	-105.51
Profit before Tax	1,449.48	6,007.10	2,549.18	4,027.00	5,422.08
Provision for Tax	381.33	1,514.90	494.07	857.70	1,709.34
Profit after Tax	1,068.15	4,492.20	2,055.11	3,169.30	3,712.74

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Shareholder's Funds	2,267.42	27,111.40	16,300.34	37,891.50	37,890.97
Minority Interest	0.00	-79.70	-24.90	38.90	1.76
Non-Current Liabilities	277.34	7,112.50	5,011.23	3,145.10	2,580.33
Current Liabilities	1,779.11	15,711.90	6,507.25	16,747.40	18,039.01
Total Liabilities	4,323.87	50,672.60	27,754.83	56,576.70	58,196.15

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Non-Current Assets	416.63	31,677.20	20,274.65	27,204.00	24,040.45
Current Assets	3,606.18	19,906.10	6,954.20	30,179.30	32,708.75
Total Assets	4,323.87	50,672.60	27,754.83	56,576.70	58,196.15
Total Debt*	0.00	11,769.50	6,021.78	7,734.10	7,676.20
Net Current Assets	1,827.07	4,194.20	446.95	13,431.90	14,669.74
Contingent Liabilities	515.18	989.90	924.77	336.14	1,358.37

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Cash From Operating Activities	903.30	2,116.60	3,121.29	5,673.70	5,526.37
Cash Flow from Investing Activities	396.98	-8,296.10	-196.42	-6,549.30	-3,458.61
Cash from Financing Activities	-737.08	5,806.90	-2,952.69	829.00	-1,269.15
Net Cash Inflow / Outflow	563.20	-372.60	-27.82	-46.60	798.61

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
ROCE (%)	66.79	21.39	13.24	13.75	12.76
ROE (%)	52.98	18.78	13.60	8.72	10.38
ROA (%)	25.34	10.03	7.36	5.89	6.86
EBIT Margin (%)	32.54	19.35	19.91	9.09	14.96
Net Margin (%)	26.05	14.92	13.64	9.15	10.42
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Revenue Growth (%)	5.75	21.11	14.16	-0.87	9.09
EBIT Growth (%)	13.66	-8.99	19.45	-55.06	6.91
Net Profit Growth (%)	12.41	-3.14	8.09	-44.66	8.63
EPS Growth (%)	11.21	4.31	12.27	-43.29	11.88
Book Value Growth (%)	16.12	13.19	13.74	12.99	16.04

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Price / Earnings	43.99	23.24	47.66	31.29	25.56
Price / Book Value	18.38	4.21	6.09	2.64	2.47
Dividend Yield (%)	2.08	0.09	0.04	0.66	0.24
EV/EBITDA	32.17	16.28	27.81	19.76	13.15
Market Cap (₹ Cr)	38,682.23	87,643.18	82,801.75	1,04,763.81	75,689.14

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Debt to Equity	0.00	0.12	0.17	0.00	0.02
Short term debt to equity ratio	--	0.16	0.04	0.16	0.16
Current Ratio	2.03	1.27	1.07	1.80	1.81
Quick Ratio	1.77	0.91	0.74	1.35	1.15
Interest Coverage	442.91	12.77	5.41	10.67	14.98

	Glaxosmithkline Pharma	Zydus Lifesciences	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Debtors to sales (%)	6.91	18.94	11.74	30.47	20.31
Asset Turnover	0.94	0.64	0.53	0.62	0.65
Receivable days	24.45	33.55	39.93	103.79	33.71
Inventory Days	40.60	33.80	51.78	79.94	59.32
Payable days	172.70	149.82	111.46	84.78	148.20
Cash Conversion Cycle	-107.65	-82.46	-19.75	98.95	-55.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.